Suppr超能文献

[过敏反应的介质。慢反应物质(SRS-A)]

[Mediators of the allergic reaction. Slow reacting substance (SRS-A)].

作者信息

Naranjo P

出版信息

Allergol Immunopathol (Madr). 1975 Jul-Aug;3(4):239-54.

PMID:5879
Abstract

The slow reacting substance of anaphylaxis (SRS-A) belongs to a group of substances which produce a slow progressive and sustained contraction of some smooth muscles. It is released by the interaction of the antigen with certain antibodies; in humans through the interaction with the IgE or reagine. The SRS-A is a heat-labile sustance, chemically unstable, of an acid character, with a low molecular weight. It is not destroyed by the action of proteolytic enzymes. Its molecular structure has not yet been elucidated. It is not found accumulated in the cells but synthesized and released by some white cells mainly by sensitized mast cells and polymorphonuclear leukocytes after challenging with the specific antigen. The SRS-A is a powerful pharmacodynamic agent, it produces contraction of the bronchial smooth muscle in doses of nanograms. It probably plays a predominant role in the physiopathology of asthma. The chain of chemical reactions elicited by antigen-antibody interaction does not end with the release of SRS-A and the other mediators (histamine, eosinophil chemotactic factor of anaphylaxis, ECF-A), on the contrary, these mediators especially SRS-A induce the release of prostaglandins of type E (PGE1 and PGE2) which produce bronchodilatation and inhibit the release of SRS-A itself, perhaps being a selfregulating mechanism. The PGF2a, on the other hand, produces bronchoconstriction. The release of SRS-A is also inhibited by the action of diethyl-carbamazine and especially by sodium chromoglicate and compound AH-7725. From the biochemical point of view it is found that the antigen Igells, a serine esterase, initiating several chemical reactions whose consequence is a decrease in the cAMP concentration. This reduction in the cAMP intracellular level is followed by synthesis and excretion of the SRS-A as well as by the aggregation of the microtubules and excretion of the stored histamine. The PGE (1 and 2) acting on one type of membrane receptor and the beta-agonist catecholamines on another produce a common phenomenon: the activation of the adenylcyclase whcih produces the increase of the concentration of cAMP and inhibits the release of mediators of the anapylactic reaction. The parasympathetic system through its chemical mediator acethylcholine, by a mechanism in whcih adenycyclase is not involved is also capable of stimulating the release of histamine and SRS-A. Something similar happens with PGF2a. In conclusion, self-regulatory mechansims for the release of mediators of the anaphylactic reactions may exist. The "perpetuation" of an asthamtic reaction would signify a failure of these self-regulatory mechanisms due to, for example, to a temporary block of the beta-adrenergic receptors, overstimulation of the alfa-receptors or insufficient production of PGE or a transformation of the PGE in PGF.

摘要

过敏反应迟缓反应物质(SRS-A)属于一类能使某些平滑肌产生缓慢进行性持续收缩的物质。它由抗原与某些抗体相互作用释放;在人类中是通过与IgE或反应素相互作用释放。SRS-A是一种热不稳定物质,化学性质不稳定,呈酸性,分子量低。它不会被蛋白水解酶的作用破坏。其分子结构尚未阐明。它不是在细胞中积累,而是由一些白细胞合成并释放,主要是致敏肥大细胞和多形核白细胞在受到特异性抗原刺激后释放。SRS-A是一种强大的药效学剂,纳克剂量就能使支气管平滑肌收缩。它可能在哮喘的病理生理学中起主要作用。抗原-抗体相互作用引发的化学反应链并不以SRS-A和其他介质(组胺、过敏反应嗜酸性粒细胞趋化因子,ECF-A)的释放而结束,相反,这些介质尤其是SRS-A会诱导E型前列腺素(PGE1和PGE2)的释放,这些前列腺素会产生支气管扩张并抑制SRS-A自身的释放,这可能是一种自我调节机制。另一方面,PGF2a会引起支气管收缩。二乙氨基甲嗪的作用,尤其是色甘酸钠和化合物AH-7725的作用也能抑制SRS-A的释放。从生化角度来看,发现抗原Igells,一种丝氨酸酯酶,引发了几个化学反应,其结果是cAMP浓度降低。细胞内cAMP水平的这种降低随后伴随着SRS-A的合成和排泄以及微管的聚集和储存组胺的排泄。作用于一种膜受体的PGE(1和2)和作用于另一种膜受体的β-激动剂儿茶酚胺产生一个共同现象:腺苷酸环化酶的激活,这会导致cAMP浓度增加并抑制过敏反应介质的释放。副交感神经系统通过其化学介质乙酰胆碱,通过一种不涉及腺苷酸环化酶的机制,也能够刺激组胺和SRS-A的释放。PGF2a也有类似情况。总之,可能存在过敏反应介质释放的自我调节机制。哮喘反应的“持续”可能意味着这些自我调节机制的失败,例如,由于β-肾上腺素能受体的暂时阻断、α-受体的过度刺激或PGE产生不足或PGE向PGF的转化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验